2025-10-23 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the provided data. The report is written in English with key numbers first, followed by analysis.

**Report on Natera Inc. (NTRA)**

**0. Executive Summary:**

Natera Inc. is a diagnostics company specializing in cell-free DNA testing.  NTRA has recently shown rapid price appreciation driven by positive news but carries significant risk, reflected in high volatility and negative long-term expected return relative to the S&P 500.  While analyst consensus leans towards "Buy", the company's profitability remains a concern, making this a high-risk, high-reward investment.

**1. Performance vs. S&P 500 (VOO):**

*   **Ticker:** NTRA
*   **Company Description:** Natera Inc. is a diagnostics company specializing in cell-free DNA testing.
*   **NTRA Cumulative Return:** 93.17%
*   **VOO Cumulative Return:** 99.36%
*   **Relative Divergence:**
    *   Current Divergence: -9.5
    *   Max Divergence: 174.8
    *   Min Divergence: -88.5
    *   Relative Divergence (Current Position within Range): 30.0

**Analysis:**  NTRA has underperformed the S&P 500, with a current cumulative return slightly lower than the index. The relative divergence of 30.0 suggests that NTRA's performance is currently positioned towards the lower end of its historical performance range relative to the S&P 500. This shows NTRA is currently underperforming the market.

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD     | Alpha   | Beta   | Cap(B) |
|------------|-----------|---------|---------|--------|--------|
| 2015-2017  | -10.0%    | 70.1%   | -34.0%  | -0.2   | 1.2    |
| 2016-2018  | 22.0%     | 80.0%   | 6.0%    | 0.1    | 1.9    |
| 2017-2019  | 50.0%     | 80.0%   | 28.0%   | 1.0    | 4.7    |
| 2018-2020  | 186.0%    | 80.5%   | 163.0%  | 1.1    | 13.7   |
| 2019-2021  | 96.0%     | 80.5%   | 49.0%   | 1.6    | 12.9   |
| 2020-2022  | -77.0%    | 80.5%   | -76.0%  | 0.1    | 5.5    |
| 2021-2023  | -194.0%   | 76.6%   | -195.0% | -1.1   | 8.7    |
| 2022-2024  | 8.0%      | 76.6%   | -13.0%  | -1.2   | 21.9   |
| 2023-2025  | 120.0%    | 76.6%   | 57.0%   | 0.1    | 25.8   |

**Analysis:** The table reveals significant volatility in NTRA's performance.
*   **CAGR:** Highly variable, ranging from negative to extremely positive values, indicating inconsistent growth.
*   **MDD:** Consistently high Maximum Drawdown, suggesting a high level of risk.
*   **Alpha:** Fluctuates widely, indicating periods of both outperformance and underperformance relative to the market.
*   **Beta:** Varies, suggesting the stock's sensitivity to market movements changes over time. Periods with beta > 1 indicate higher volatility than the market.

**2. Recent Stock Price Movement:**

*   **Last Price:** 186.88
*   **Last Market Data:**
    *   Price: 188.02
    *   Previous Close: 186.88
    *   Change: 0.61
*   **5-day Moving Average:** 183.43
*   **20-day Moving Average:** 170.79
*   **60-day Moving Average:** 164.32

**Analysis:** The stock price is above all three moving averages, suggesting an uptrend.  The recent change of 0.61 from the previous close indicates a slight positive movement, but not a major gap that would signal extreme volatility.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 78.99 (Overbought)
*   **PPO:** 1.09
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (6 shares - Very Safe - MRI:0.90)
*   **Delta Previous Relative Divergence (20-day):** 3.6 (+)
*   **Expected Return (%):** -108.8%

**Analysis:**

*   **MRI:** The MRI suggests a high investment recommendation, but this should be interpreted cautiously given the other risk factors.
*   **RSI:**  The high RSI indicates the stock is overbought and may be due for a correction or consolidation.
*   **PPO:** A positive PPO suggests a bullish trend.
*   **Delta Previous Relative Divergence:** Positive change in relative divergence confirms the recent upward trend.
*   **Expected Return:** The significantly negative expected return is a major red flag, suggesting that even with dollar cost averaging the performance relative to the S&P is expected to decline significantly.

**4. Recent News & Significant Events:**

*   **October 21, 2025:** Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
*   **October 20, 2025:** Why Are Natera (NTRA) Shares Soaring Today
*   **October 20, 2025:** Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
*   **October 16, 2025:** Natera Named to Fast Company’s Next Big Things in Tech List
*   **October 14, 2025:** Liberty All-Star® Growth Fund, Inc. September 2025 Monthly Update
*   **October 13, 2025:** The Bull Case For Natera (NTRA) Could Change Following Breakthrough Study Results for Signatera Platform

**Analysis:**  Recent news is overwhelmingly positive, citing reasons for the stock's surge and highlighting potential for future growth.  The IMvigor011 trial success is a particularly significant positive catalyst. The Breakthrough Study Results for Signatera Platform is another key driver.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (~1.53)
*   **Opinions:** 19
*   **Target Price:**
    *   Average: 193.95
    *   High: 235.00
    *   Low: 37.00

**Analysis:** Analyst consensus leans towards "Buy" with a significant average target price upside. However, the wide range between the high and low target prices suggests considerable uncertainty among analysts regarding the stock's future performance.

**5. Recent Earnings Analysis:**

| 날짜         | EPS   | 매출       |
|--------------|-------|------------|
| 2025-08-08   | -0.74 | 0.55 B$    |
| 2025-05-09   | -0.5  | 0.50 B$    |
| 2024-11-12   | -0.26 | 0.44 B$    |
| 2024-08-09   | -0.3  | 0.41 B$    |
| 2025-08-08   | -0.3  | 0.41 B$    |

**Analysis:** The company is consistently losing money on a per-share basis (negative EPS), despite growing revenues. The most recent EPS is particularly concerning.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $0.55B    | 63.41%        |
| 2025-03-31   | $0.50B    | 63.12%        |
| 2024-12-31   | $0.48B    | 62.94%        |
| 2024-09-30   | $0.44B    | 61.79%        |
| 2024-06-30   | $0.41B    | 58.83%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE        |
|--------------|-----------|------------|
| 2025-06-30   | $1.25B    | -8.10%     |
| 2025-03-31   | $1.24B    | -5.40%     |
| 2024-12-31   | $1.20B    | -4.50%     |
| 2024-09-30   | $0.88B    | -3.60%     |
| 2024-06-30   | $0.84B    | -4.48%     |

**Analysis:**  Revenue is growing, and profit margins are relatively high. However, the negative Return on Equity (ROE) confirms that the company is not generating profits from shareholder investments.

**7. Comprehensive Analysis:**

Natera Inc. (NTRA) is a high-growth, high-risk stock. Recent positive news has fueled a price surge, and analyst sentiment is generally positive. However, several factors warrant caution:

*   **Lack of Profitability:** The company is consistently losing money (negative EPS and ROE). This is a major concern, even for a growth stock.
*   **High Volatility:** The historical data shows significant price swings (high MDD).
*   **Overbought Condition:** The high RSI suggests the stock is due for a correction.
*   **Negative Expected Return:** The projected underperformance relative to the S&P 500, even with dollar cost averaging, is a serious warning.

**Conclusion:**

NTRA presents a speculative investment opportunity. The potential upside is significant if the company can achieve profitability and sustain its growth trajectory. However, the risks are substantial, and investors should be prepared for potential losses. A careful assessment of risk tolerance is crucial before investing in NTRA. While the MRI shows "High Investment Recommended," this contradicts the negative expected return. So, investment should be approached with caution.
